Announcement of the results of phase 1 combined use at the American Society of Clinical Pharmacology
Target additional indications until combination therapy
Daewoong Pharmaceutical(132,000 +1.15%)Announced on the 19th that the clinical results of Inabogliflozin, a type 2 diabetes treatment substance, were announced at the American Society of Clinical Pharmacology, which was conducted online.
We introduced the results of phase 1 clinical trials confirming the drug interaction when inabogliflozin and metformin were taken together. As a result of comparing the blood concentrations of drugs in combination with inabogliflozin or metformin alone, there was no significant difference, so it was confirmed that the two drugs did not affect each other.
Professor Jang In-jin of the Department of Clinical Pharmacology, Seoul National University Hospital, who is in charge of the study, said, “Drug interaction was not reported when Inabogliflozin and metformin were used in combination throughout the clinical phase. No, it was confirmed that the safety was confirmed when administered concurrently.”
Daewoong Pharmaceutical has been approved for phase 3 clinical trials from the Ministry of Food and Drug Safety based on the results of phase 1 clinical trials using Inabogliflozin and metformin.
“We are developing three indications at the same time, from single therapy to combination therapy,” said Park Hyun-jin, head of Daewoong Pharmaceutical’s development department. “I will spur development of Rosin as the best new drug in the family.”
Inabogliflozin is a new drug for suppressing diabetes mellitus’SGLT-2′ being developed by Daewoong Pharmaceutical for the first time among Korean pharmaceutical companies. In phase 2 clinical trials administered alone in type 2 diabetic patients, superior blood sugar-lowering effects were confirmed by additionally reducing glycated hemoglobin compared to existing SGLT-2 inhibitors. It also proved its safety by reducing side effects that may occur due to the mechanism. Daewoong Pharmaceutical is developing Inabogliflozin as the best-in-class new drug in the SGLT-2 inhibitor family. It is aiming to be released in Korea in 2023.
In Korea, metformin is recommended as a first-line treatment for diabetic patients. Various combination therapies are recommended depending on the patient’s condition. In addition, SGLT-2 inhibitors and’GLP-1′ receptor agonists are recommended first for diabetic patients with cardiovascular disease.
Reporter Minsoo Han [email protected]
Ⓒ Hankyung.com prohibits unauthorized reproduction and redistribution